Latest Developments in the Treatment of Hepatocellular Carcinoma
|
|
- Steven Osborne
- 5 years ago
- Views:
Transcription
1 Latest Developments in the Treatment of Hepatocellular Carcinoma Roniel Cabrera, MD MS Associate Professor of Medicine Director of Hepatology and Medical Director of Liver Transplantation Division of Gastroenterology, Hepatology and Nutrition University of Florida Gainesville, Florida
2 Objectives Discuss epidemiology, risk factors, and screening in hepatocellular carcinoma (HCC) Review diagnosis, tumor staging and importance of cirrhosis assessment in the complete staging of HCC Early and Intermediate Stage HCC Current Best Practices Advanced HCC Latest developments in treatment Importance of early referral and multidisciplinary care
3 Hepatocellular Carcinoma (HCC) Common malignancy worldwide 5th most common cancer worldwide 2nd leading cause of cancer death ~600,000 deaths annually US incidence has more than tripled over the last three decades Estimated new cases: ~40,000 new cases annually Fastest rising cause of cancer related death in US, Dismal 5-year survival <15% 85%-95% of HCC cases occur in cirrhotic livers Leading cause of death in cirrhosis Complex malignancy Heterogeneous etiologies - HCV, HBV, NAFLD, Alcohol Complex molecular carcinogenesis Mittal S, et al. J Clin Gastroenterol. 2013;47:S2-S6. Weledji EP, et al. Ann Med Surg (Lond). 2014;3: Ferlay J, et al. Int J Cancer. 2010;127: Siegel R, et al. CA Cancer J Clin. 2014;64:
4 Natural History of Untreated HCC in a US VA Cohort with HCV as the Predominant Etiology Mortality by BCLC Stage (n=518) Khalaf N et al. Clin Gastroenterol Hepatol 2016.
5 Risk of HCC in HCV Patients Treated with DAAs De Novo HCC risk unlikely to be increased by HCV therapy, risk likely relates to underlying disease state Small percentage may have undetected HCC Residual risk for HCC after SVR/cure in a VA Cohort (n=22,500) Recurrent HCC, particularly after noncurative treatment is more controversial Mechanism unclear reduced immune response to HCC and/or regeneration post HCV clearance promotes HCC growth Some transplant centers wait until HCC controlled for 6-12 months prior to initiating HCV therapy Needs more study HCC Recurrence after Successful HCC Treatment and DAA Therapy Kanwal F et al Gastroenterology Conti et al EASL Reig M et al EASL 2017.
6 HCC Surveillance: Guideline Recommendations Cirrhosis (any cause) HCV F4 and F3 with SVR HBV Asian males > 40 years Asian females > 50 years Africans > 20 years Family history of HCC Ultrasound with AFP every 6 months Strategies to improve US: Abbreviated MRI T2 weighted and DWI AFP Normal in 40% of patients with HC Normal in small HCC Values >200 ng/ml high PPV in cirrhotic patients with a mass Strategies to improve Rate of change over 6-12 months and combining with Age, PLT, ALT Majority of patients (~80%) with cirrhosis are not receiving HCC surveillance as recommended by guidelines. AASLD website. Available at: EASL Website. Available at:
7 Normal Liver Ultrasound but AFP >15,000
8 AASLD Diagnostic Criteria for HCC: Liver Nodule on Surveillance Ultrasound or High AFP in a Cirrhotic Liver Small nodule <1 cm >1 cm Repeat US at 3 months 4-phase MDCT / dynamic contrast enhanced MRI Growing/changing character Stable Arterial hypervascularity AND venous or delayed phase washout Investigate according to size Yes Other contrast enhanced study (CT or MRI) No HCC Arterial hypervascularity AND venous or delayed phase washout Biopsy Yes No Bruix J, et al. Hepatology. 2011;53: Available at
9 Radiologic Diagnosis of HCC in Cirrhosis Arterial phase enhancement Venous phase washout Cabrera R, Nelson DR. Aliment Pharmacol Ther ;31(4):
10 Liver Imaging Reporting and Data System (LI-RADS) Standardize Classification of Liver Nodules on Contrast Enhanced Cross-Sectional Imaging
11 Diagnosis of HCC: To Biopsy or Not? Yes Imaging is inconsistent with HCC Distinguish HCC from Intrahepatic Cholangiocarcinoma (CCA) Poor prognosis 5 year overall survival 8-50% High recurrence rates 30-40% Avoids inappropriate treatment and misleading cure May be required for experimental treatments May permit personalized therapy No Not always feasible Not needed if high diagnostic certainty based on imaging Risk Hemorrhage Tumor seeding (2.7% overall incidence) Risk of False negatives up to 1/3 of biopsies may delay treatment continue to monitor lesion with imaging **Biopsy is based on clinical picture** No high risk factors, Normal AFP, Non-classic radiographic features Heuman DM, et al. Eur J Intern Med. 2012;23: Rana A et al. Curr Opin Gastroenterol. 2012;28(3): Lee et al Liver Transpl 2018.
12 Survival by Child Pugh Class Natural History of Cirrhosis Impact HCC Outcome Observational HCC Treatment Study (GIDEON) Advanced HCC Child-Pugh B experienced more liver-associated AEs Time To Progression (TTP) Child-Pugh A, 4.2 months Child-Pugh B, 3.6 months Median Overall Survival (OS): Child-Pugh A, 10.3 months Child-Pugh B, 4.9 months Lencioni Int J Clin Pract 2012; Venook. ASCO GI (abstr 157); Marrero ASCO (abstr 4001). Pooled analysis on prognosis from 118 studies (n=23,797) Stage Clinical Criteria 1-yr Mortality 1 No Varices 1% 2 Presence of Varices 3% 3 Presence of Ascites 20% 4 GI bleeding 54% 5 Renal failure, Infection 67% D Amico G et al. Journal of Hepatology 44 (2006)
13 BCLC Staging and Treatment Strategy HCC PS 0, Child-Pugh A Okuda 1-2, PS 0-2, Child-Pugh A-B Okuda 3, PS > 2, Child-Pugh C Very early stage (0) Single < 2 cm Carcinoma in situ Early stage (A) Single or 3 nodules < 3 cm, PS 0 Intermediate stage (B) Multinodular, PS 0 Advanced stage (C) Portal invasion, N1, M1, PS 1-2 Terminal stage (D) Single Portal pressure/bilirubin Increased 3 nodules 3 cm Associated diseases Normal No Yes Resection Liver transplantation RFA/PEI Curative treatments (30%); 5-yr survival: 40%-70% TACE Sorafenib RCTs (50%); 3-yr survival: 10%-40% Symptomatic (20%); survival <3 mos MWA Llovet JM, et al. Journal of the National Cancer Institute. 2008;100: TARE (Y90) Lenvatinib, Regorafenib, Cabozantinib, Nivolumab
14 67 year old white male with HBV cirrhosis on antiviral therapy with good viral control. Abnormal US on surveillance. AFP = 5. Cirrhotic liver, stigmata of portal hypertension. Single 2.5 cm arterially enhancing lesion in the left lobe of the liver. Single Liver Mass
15 Multidisciplinary Care of Patients with HCC Palliative care Medical oncology Hepatology Tumor Registry Radiology Nursing Primary care provider Clinical research Interventional radiology Surgery Radiation oncology Pt
16 Very Early Stage and Early-Stage HCC: Current Best Practices Very early stage (0) Single < 2 cm (T1) Early stage (A) Single <5 cm or 3 < 3 cm (T2)
17 What is the best treatment option? C U R A T I V E Surgery: Liver Transplantation Resection Thermal Ablation: Microwave (MWA) Radiofrequency (RFA) P a l l i a t i v e Transarterial: Chemoembolization 90 Y microspheres Systemic Therapies: Sorafenib,?Lenvatinib Regorafenib, Nivo, Cabozantinib Clinical Trials
18 Liver Transplantation for HCC Accounts >20% of all liver transplants 5-year survival of > 70% Automated MELD exception if meets all three criteria: 1) Lesion must be >2 cm and <5cm (T2) 2) Arterial enhancement 3) Washout on venous phase or Capsule enhacement Growth by > 50% 6 month waiting period MELD Score begins at 28 after a 6 month waiting period Increases every 3 months if within criteria then caps at 34 Applying AFP as exclusion criterion Patients with AFP >1,000 ng/ml need to show a decrease to <500 ng/ml Milan Criteria Remains the Standard Criteria UCSF Down Staging Criteria Mazzaferro et al. NEJM Yo FY et al Hepatology UNOS HCC Policy.
19 Curative Treatments Resection Ablation Transplant Noncirrhotics Choice of therapy Cirrhotics Reserved for CTP A Avoid R hepatectomy Best for solitary HCC < 30% eligible Survival 5 yrs: 50-60% Effective when < 3 cm Multiple modalities Thermal, Combo for > 3cm Y90/Radiation Segmentectomy Stereotactic radiation Minimally invasive Survival 5 yrs: 50-60% Cures both MELD exception Milan criteria Downsizing Demand > supply Survival 5 yrs: 70% Recurrence 5 yrs: 70% Recurrence 5 yrs: 70% Recurrence 5 yrs: 15% *No proven adjuvant therapy to decrease recurrence* Belghiti J, et al. HPB (Oxford). 2005;7: Bruix J, et al. Hepatology. 2011;53: Feng Q, et al. J Cancer Res Clin Oncol. 2015;141:1-9. Sapisochin G, et al. at Rev Gastroenterol Hepatol. 2017;14: Thuluvath PJ, et al. Liver Transpl. 2009;15:
20 Radiation Segmentectomy Above 3 cm efficacy of RFA is diminished Y90 radiation segmentectomy is Y90 infusion limited to 2 hepatic segments allows accurate tumor targeting while sparing surrounding parenchyma (A) MRI a surface segment 4 HCC adjacent to the gallbladder, falciform ligament, and liver capsule (B) Angiography of segment 4 lesion 300 Gy (C) Complete mrecist tumor necrosis at 18 months follow-up. No viable tumor found at explant.
21 Y90 Radiation Lobectomy in Preparation for Resection Contra-lateral hypertrophy
22 Multifocal HCC, Large Bi-Lobar 70 year old white male with HCV cirrhosis noted with abnormal ultrasound. AFP =11. Cirrhotic liver multiple arterially enhancing lesions in the right and left hepatic lobes. 2 large enhancing lesion in the superior right hepatic lobe which measure 5.6 x 4.9 cm and 5.7 x 5.6 cm.
23 Intermediate Stage HCC: Current Best Practices
24 Probability of Survival (%) Palliative TACE Prolongs Survival in Unresectable HCC Chemoembolization (n = 40) Control (n = 35) OR (95% CI) Log-rank P < Mos Since Randomization Pts at Risk, n Author, Journal Yr Pts Lin, Gastroenterology GETCH, NEJM Bruix, Hepatology Pelletier, Hepatol Lo, Hepatology Llovet, Lancet Overall 503 Median survival: ~ 20 months z = 2.3 P =.017 Llovet J, et al. Lancet. 2002;359: Llovet J, et al. Hepatology. 2003;37:
25 Liver Directed Therapies: Embolotherapy Techniques Technique Mechanism Pros Cons TAE Conventional TACE (ctace) DEB-TACE Radioembolization Ischemic necrosis induced at arteriolar level via permanent embolic (eg, small particles) Intrahepatic chemotherapy with embolization by ethiodized oil Intrahepatic chemotherapy + embolization with slowrelease drug-eluting beads Radiation necrosis induced by beta-emitting Yttrium-90 microspheres Low cost, no chemotherapy adverse events Strongest evidence supporting benefit from RCT data More standardized than ctace, less systemic release of chemotherapy May improve TTP Fewer sessions required No postembolization syndrome May be safer in adv disease with PVT Radiation segmentectomy may be curative FLR hypertrophy from radiation lobectomy can provide tumor control and facilitate resection Postembolization syndrome may cause PEs Intra-operator technical variation (ctace) Systemic release of chemotherapy (ctace) Postembolization syndrome More expensive than ctace Postembolization syndrome Cost: 2-3x more expensive Requires multidisciplinary coordination Nontarget delivery may cause severe ulceration Potential biliary toxicity Radiation-induced liver disease Kishore S, et al. Curr Oncol Rep. 2017;19:40.
26 Radioembolization Using Yttrium-90 Single institution cohort study, Glass microsphere (Therasphere) Endpoints: Response rate,* TTP,* survival, toxicity 273/291 (94%) of patients had follow-up imaging 58% Downstaged, 32 transplanted Response rate 42% (WHO) and 57% (EASL) No GI ulcers Stage B 83 (28%) Stage C 152 (52%) TTP 13.3 months 6 months Overall Survival 17.2 months Child A = 17.3 months Child B = 13.5 months 7.3 months Child A = 13.8 months Child B = 6.4 months Salem R et al. Gastroenterology. 2010;138(1):52-64.
27 Randomized Study of ctace vs Radioembolization Overall Survival Time To Progression Single center phase 2 RCT. Primary endpoint: TTP 45 patients randomized 1:1 to TACE vs. Y90 Child-Pugh: 76% vs. 42% (P=0.08). BCLC stage A/B 81%/19% vs 75%/25% (P=0.73) Similar overall survival (17.7 vs 18.6 mon) but significantly longer TTP with Y90. Salem R et al. Gastro 2016;151:
28 Case: Progression After TACE A 57-yr-old male is diagnosed with BCLC stage B HCC based on compensated cirrhosis (Child-Pugh A), liver-only disease, and ECOG PS 0 After 2 TACE sessions, angiography revealed obstructed hepatic artery blood flow to the tumor and surrounding sites with disseminated disease
29 Case: Advanced HCC Arterial phase Venous phase Delayed phase
30 Management of Advanced HCC
31 Probability of Survival Probability of Radiologic Progression Palliation of Advanced HCC: Sorafenib Prior to 2007, no therapy was of benefit in advanced HCC SHARP trial: CTP A pts with advanced HCC randomized to sorafenib 400 BID vs placebo Sorafenib delayed progression and prolonged survival from 7.9 to 10.7 mos Led to approval by the FDA in 2007 for palliation of advanced-stage HCC It remains the only approved first-line systemic therapy for unresectable/advanced HCC Pts at Risk, n Sorafenib Placebo Pts at Risk. n Sorafenib Placebo 0 Time to Radiologic Progression P <.001 Sorafenib Placebo Mos Since Randomization P <.001 OS Sorafenib Placebo Mos Since Randomization Llovet JM, et al. N Engl J Med. 2008;359: Desai JR, et al. J Gastrointest Oncol. 2017;8:
32 Y90 vs Sorafenib in locally advanced HCC + PVT (Stage B and C) Phase 3 SARAH, Europe/France Vilgrain V, et al. Lancet Oncology Dec Phase 3 SIRveNIB, Asia-Pacific Chow et al. Journal Clinical Onc July Median Overall Survival Y90 /SIRT 8.0 months Sorafenib 9.9 months HR 1.15 (95% CI: ; P=.18) Median Overall Survival Y90 /SIRT 8.8 moths Sorafenib 10.0 months HR 1.12 (95% CI: ; P=.36) *Y90 versus Sor: Radioembolization has no clinical benefit versus sorafenib in advanced HCC. *SORAMIC Trial: Y90 plus Sorafenib (n=216) versus Sorafenib (n=208) alone did not improve OS -SIRT + Sor, 12.1 months versus Sor alone 11.5 months (Presented EASL 2018, SORAMIC Trial)
33 Lenvatinib vs Sorafenib in 1L Treatment in Advanced HCC Lenvatinib targets VEGFR axis as well as FGFR 1-3 Compared lenvatinib to sorafenib in the front line setting with a non-inferiority design (Phase 3 REFLECT) Patients with unresectable HCC randomized 1:1 Len (n=478: <60kg 8mg, >60kg 12 mg) Sor (n=476) Excluded patients with Main PV BCLC Stage B/C Len 22% / 78% Sor 19% / 81% Lenvatinib is noninferior to sorafenib in OS Statistically significant improvements in PFS, TTP, and ORR for lenvatinib vs sorafenib First phase 3 trial in HCC to be positive since sorafenib 2007 (SHARP trial) Outcome mos, mos (95% CI) mpfs, mos (95% CI) mttp, mos (95% CI) Lenvatinib (n = 478) 13.6 ( ) 7.4 ( )* 8.9 ( )* ORR, n (%) 115 (24.1)* Sorafenib (n = 476) 12.3 ( ) 3.7 ( ) 3.7 ( ) 44 (9.2) HR 0.92 ( ) 0.66 ( ) 0.63 ( ) Kudo M et al. Lancet Mar L= 1 st Line
34 RESORCE Phase 3: Regorafenib vs Placebo in 2L Advanced HCC Pts with HCC with documented radiologic progression on sorafenib (N= 573) Randomized 2:1 to Rego (n=379) vs Placebo (n=194). Tolerated sorafenib > 400 mg/day for at least 20 of the last 28 days of treatment Rego 160 mg PO QD, Days 1-21 of 28-day cycle Approved by FDA on April 2017 for HCC previously treated with sorafenib (2L) Probability of Survival (%)100 Placebo Regorafenib (n = 379) Placebo (n = 194) mos, mos (HR: 0.63; 95% CI: ; 1-sided P <.0001) Regorafenib Mos From Randomization 33 Outcomes of the Sequence of Sorafenib Followed by Regorafenib or Placebo Outcomes From start of sorafenib Regorafenib (n=374) Placebo (n=193) Median survival, months Estimated survival, at 3 yrs 31% 20% Estimated survival, at 5 yrs 16% 3% 2L=2nd line. Bruix J, et al. Lancet. 2017;389: Finn RS et al J hepatol 2018.
35 CELESTIAL Phase 3: Cabozantinib vs Placebo in 2L Advanced HCC Cabozantinib targets VEGFR axis and MET. Pts with advanced HCC radiologic progression on sorafenib No more than 2 prior systemic therapies Randomized 2:1 to Cabo 60 mg qd (n=470) vs Placebo (n=237) BCLC Stage C: 85% and 84% Cabozantinib significantly prolonged OS in patients with previously treated advanced HCC. Corresponding to this survival benefit, a longer duration of PFS was also observed Positive Phase 3 in 2L setting for advanced HCC with OS and PFS benefit Abou-Alfa GK et al. NEJM July L = second line
36 Nivolumab in Advanced HCC - Phase 1/2 CheckMate 040 FDA approval in September 2017 in 2L Advanced HCC for patients previously treated with sorafenib Approval contingent on additional confirmatory/phase 3 studies. El-Khoueiry et al Lancet 2017.
37 Conclusions Burden of HCC is increasing Screen your at risk patients with cirrhosis for HCC with ultrasound and AFP every 6 months for early detection Early-stage HCC (BCLC A) may be cured with - Thermal ablation, Resection and/or Liver transplantation Intermediate stage HCC (BCLC B) palliated with TACE and Y90 Local measures often fail in tumors with aggressive biology Advanced stage HCC (BCLC C) palliated with Sorafenib New 1L (Lenvatinib) and 2L therapies (Regorafenib, Cabozantinib, Nivolumab) Application of therapies may be limited by severity of cirrhosis Multidisciplinary teams are important for optimal outcome
38 Thank You!
Paul Martin MD FACG. University of Miami
Paul Martin MD FACG University of Miami 1 Liver cirrhosis of any cause Chronic C o c hepatitis epat t s B Risk increases with Male gender Age Diabetes Smoking ~5% increase in HCV-related HCC between 1991-28
More informationCurrent Standards of Care of Hepatocellular Carcinoma? Prof. Mohsen Mokhtar M.D Cairo Univ.
Current Standards of Care of Hepatocellular Carcinoma? Prof. Mohsen Mokhtar M.D Cairo Univ. Disclosures Honoraria Received : Amgen, Astra Zeneca, Bohrengier, Hikma,Hospira, GSK, Lilly, Merck, MSD, Novartis,
More informationHepatocellular Carcinoma. Markus Heim Basel
Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749
More informationIl treatment plan nella terapia sistemica dell epatocarcinoma
Il treatment plan nella terapia sistemica dell epatocarcinoma M. Iavarone, MD PhD CRC A.M. e A. Migliavacca Center for the Study of Liver Disease Division of Gastroenterology and Hepatology Fondazione
More informationSurveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More informationΗπατοκυτταρικός Καρκίνος Συστηματική Θεραπεία. Θωμάς Μακατσώρης Επίκ. Καθ. Παθολογίας-Ογκολογίας Ιατρική Σχολή Πανεπιστημίου Πατρών 11/5/2018
Ηπατοκυτταρικός Καρκίνος Συστηματική Θεραπεία Θωμάς Μακατσώρης Επίκ. Καθ. Παθολογίας-Ογκολογίας Ιατρική Σχολή Πανεπιστημίου Πατρών 11/5/2018 Advisory Board Disclosures Roche, Boeringer, Sanofi, Astra Zeneca,
More informationHepatocellular Carcinoma: A major global health problem. David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center
Hepatocellular Carcinoma: A major global health problem David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center Hepatocellular Carcinoma WORLDWIDE The #2 Cancer Killer Overall cancer
More informationHepatocellular Carcinoma: Diagnosis and Management
Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm
More informationMULTI-DISCIPLINARY MANAGEMENT OF INTERMEDIATE STAGE HCC
Dr Apoorva Gogna MBBS FRCR FAMS Consultant Interventional Radiology Center Department of Diagnostic Radiology SingaporeGeneral Hospital MULTI-DISCIPLINARY MANAGEMENT OF INTERMEDIATE STAGE HCC CASE HISTORY
More informationLiver resection for HCC
8 th LIVER INTEREST GROUP Annual Meeting Cape Town 2017 Liver resection for HCC Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre The liver is almost unique in that treatment of the
More informationAdvances in percutaneous ablation and systemic therapies for hepatocellular carcinoma
Advances in percutaneous ablation and systemic therapies for hepatocellular carcinoma Paris Hepatology Congress 2019 Pierre Nahon Service d Hépatologie Hôpital Jean Verdier Bondy Université Paris 13 INSERM
More informationTREATMENT FOR HCC AND CHOLANGIOCARCINOMA. Shawn Pelletier, MD
TREATMENT FOR HCC AND CHOLANGIOCARCINOMA Shawn Pelletier, MD Treatment for HCC Treatment strategies Curative first line therapy Thermal ablation vs Resection vs Transplant Other first line therapies TACE
More informationWHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC?
WHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC? Dr. Alexander Kim Chief, Vascular and Interventional Radiology, Medstar Georgetown University Hospital, USA DISCLAIMER Please note: The views
More informationSIRT for Intermediate and Advanced HCC
Pamplona, junio de 2008 SIRT for Intermediate and Advanced HCC Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain 90 Y-RE MRI SPECT FUSION 90 Y-RE = Yttrium-90 radioembolization Sangro
More informationUnmet needs in intermediate HCC. Korea University Guro Hospital Ji Hoon Kim
Unmet needs in intermediate HCC Korea University Guro Hospital Ji Hoon Kim BCLC HCC Stage 0 PST 0, Child Pugh A Stage A C PST 0 2, Child Pugh A B Stage D PST > 2, Child Pugh C Very early stage (0) 1 HCC
More informationNew Therapies in HCC Bruno Sangro Clínica Universidad de Navarra. IdISNA. CIBERehd. Pamplona, Spain
New Therapies in HCC Bruno Sangro Clínica Universidad de Navarra. IdISNA. CIBERehd. Pamplona, Spain PHC 2018 - www.aphc.info EASL-EORTC Guidelines EASL EORTC Guidelines. J Hepatol. 2012;56:908-43. Systemic
More informationHepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer
More informationLiver transplantation: Hepatocellular carcinoma
Liver transplantation: Hepatocellular carcinoma Alejandro Forner BCLC Group. Liver Unit. Hospital Clínic. University of Barcelona 18 de marzo 2015 3r Curso Práctico de Transplante de Órganos Sólidos Barcelona
More informationManagement of HepatoCellular Carcinoma
9th Symposium GIC St Louis - 2010 Management of HepatoCellular Carcinoma Overview Pierre A. Clavien, MD, PhD Department of Surgery University Hospital Zurich Zurich, Switzerland Hepatocellular carcinoma
More informationHepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC
Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC Objectives Identify patient risk factors for hepatocellular carcinoma (HCC) Describe strategies
More informationHCC: Is it an oncological disease? - No
June 13-15, 2013 Berlin, Germany Prof. Oren Shibolet Head of the Liver Unit, Department of Gastroenterology Tel-Aviv Sourasky Medical Center and Tel-Aviv University HCC: Is it an oncological disease? -
More informationA) PUBLIC HEALTH B) PRESENTATION & DIAGNOSIS
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary), April 2017 by Dr. Jenny Ko (Medical Oncologist, Abbotsford Centre, BC Cancer
More information9th Paris Hepatitis Conference
9th Paris Hepatitis Conference Paris, 12 January 2016 Treatment of hepatocellular carcinoma: beyond international guidelines Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow Units
More informationHCC Imaging and Advances in Locoregional Therapy. David S. Kirsch MD Ochsner Clinic Foundation
HCC Imaging and Advances in Locoregional Therapy David S. Kirsch MD Ochsner Clinic Foundation -Nothing to disclose Hepatic Imaging Primary imaging modalities include: US CT MR Angiography Nuclear medicine
More informationLocoregional Therapy for Hepatoma
Locoregional Therapy for Hepatoma Robert D. Crane, MD Interventional Radiology Virginia Mason How do we know a liver mass is HCC? HCC : Bx Of pts getting liver transplant only ~ 5% had Bx to establish
More information100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days
100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days TheraSphere [US package insert]. Surrey, UK: Biocompatibles UK Ltd,
More informationIS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?
IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views
More informationLocoregional Treatments for HCC Applications in Transplant Candidates. Locoregional Treatments for HCC Applications in Transplant Candidates
Locoregional Treatments for HCC Applications in Transplant Candidates Matthew Casey, MD March 31, 2016 Locoregional Treatments for HCC Applications in Transplant Candidates *No disclosures *Off-label uses
More informationHCC with Intrahepatic Portal vein Tumour Should Be Treated by Systemic Therapy Rather Than Transarterial Therapy (Pros)
HCC with Intrahepatic Portal vein Tumour Should Be Treated by Systemic Therapy Rather Than Transarterial Therapy (Pros) Yi-Hsiang Huang, MD, Ph.D. Professor, Division of Gastroenterology & Hepatology,
More informationRiunione Monotematica A.I.S.F The future of liver diseases. HEPATIC NEOPLASMS The challenge for new drugs
Riunione Monotematica A.I.S.F. 2016 The future of liver diseases Milan 13 th -15 th October 2016 Centro Congressi Fondazione Cariplo HEPATIC NEOPLASMS The challenge for new drugs Massimo Iavarone Gastroenterology
More information12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval
12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval ARMANDO SANTORO Roma 10-6-2016 SORAFENIB APPROVAL 29 OCTOBER 2007 Marketing authorization
More informationStudy Objective and Design
Randomized, Open Label, Multicenter, Phase II Trial of Transcatheter Arterial Chemoembolization (TACE) Therapy in Combination with Sorafenib as Compared With TACE Alone in Patients with Hepatocellular
More informationCelsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging
Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging Ronnie T.P. Poon, MBBS, MS, PhD Chair Professor of Hepatobiliary and Pancreatic Surgery Chief of Hepatobiliary and Pancreatic Surgery
More informationSEQUENCING OF HCC TREATMENT. Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA
SEQUENCING OF HCC TREATMENT Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA February 2018 DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationAn Update on Hepatocellular Carcinoma. Ed Gane NZ Liver Transplant Unit
An Update on Hepatocellular Carcinoma Ed Gane NZ Liver Transplant Unit Hepatocellular Carcinoma has a High Burden of Disease APSCVIR March 2018 Lung Liver Colon/Rectal Stomach Breast Cervix Uteri Esophagus
More information6/16/2016. Treating Hepatocellular Carcinoma: Deciphering the Clinical Data. Liver Regeneration. Liver Regeneration
Treating : Deciphering the Clinical Data Derek DuBay, MD Associate Professor of Surgery Director of Liver Transplant Liver Transplant and Hepatobiliary Surgery UAB Department of Surgery Liver Regeneration
More informationUPDATE OF EASL CLINICAL PRACTICE GUIDELINES: MANAGEMENT OF HEPATOCELLULAR CARCINOMA*
UPDATE OF EASL CLINICAL PRACTICE GUIDELINES: MANAGEMENT OF HEPATOCELLULAR CARCINOMA* Dr. Catherine Frenette Medical Director of Liver Transplantation, Scripps Green Hospital, La Jolla, CA, USA May 2018
More information9/10/2018. Liver Transplant for Hepatocellular Carcinoma (HCC): What is New? DISCLOSURES
UCSF Transplant 2018: Pioneering Advances in Transplantation DISCLOSURES Liver Transplant for Hepatocellular Carcinoma (HCC): What is New? I have no relevant commercial interests or relationships to report
More informationHEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT
HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT INTRODUCTION: Hepatocellular carcinoma (HCC): Fifth most common cancer worldwide Third most common cause of cancer mortality In Egypt: 2.3%
More informationIl Tumore del Fegato Prospettive Future nel Trattamento dei Tumori Gastrointestinali
Il Tumore del Fegato Prospettive Future nel Trattamento dei Tumori Gastrointestinali Lorenza Rimassa Medical Oncology Unit Humanitas Cancer Center Humanitas Research Hospital Rozzano (Milano) Disclosures
More informationThe Current Champion: Angiogenesis inhibitors
The Current Champion: Angiogenesis inhibitors Baek-Yeol RYOO University of Ulsan College of Medicine ASAN Medical Center Dept. of Oncology Seoul, Korea Survival probability Sorafenib: Overall Survival
More informationHepatocellular carcinoma: Intra-arterial treatments
Hepatocellular carcinoma: Intra-arterial treatments Irene Bargellini U.O. Radiologia Interventistica Azienda Ospedaliero Universitaria Pisana IRENE BARGELLINI,MD UO RADIOLOGIA INTERVENTISTICA, AZIENDA
More informationAdvances in Systemic Therapy Hepatocellular Carcinoma (HCC) Dr ZEE Ying Kiat HASLD Conference Ho Chi Minh City, 18 December 2016
Advances in Systemic Therapy for Hepatocellular Carcinoma (HCC) Dr ZEE Ying Kiat HASLD Conference Ho Chi Minh City, 18 December 2016 Scope Background Staging and treatment strategies Current systemic therapy
More informationSurveillance for HCC Who, how Diagnosis of HCC Surveillance for HCC in Practice
Surveillance for Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationGuidelines for SIRT in HCC An Evolution
Guidelines for SIRT in HCC An Evolution 2 nd Asia Pacific Symposium on Liver- Directed Y-90 Microspheres Therapy 1st November 2014, Singapore The challenge of HCC Surgery is potentially curative in early
More informationHepatobiliary Malignancies Retrospective Study at Truman Medical Center
Hepatobiliary Malignancies 206-207 Retrospective Study at Truman Medical Center Brandon Weckbaugh MD, Prarthana Patel & Sheshadri Madhusudhana MD Introduction: Hepatobiliary malignancies are cancers which
More informationEmbolotherapy for Cholangiocarcinoma: 2016 Update
Embolotherapy for Cholangiocarcinoma: 2016 Update Igor Lobko,MD Chief, Division Vascular and Interventional Radiology Long Island Jewish Medical Center GEST 2016 Igor Lobko, M.D. No relevant financial
More informationEASL-EORTC Guidelines
Pamplona, junio de 2008 CLINICAL PRACTICE GUIDELINES: PARADIGMS IN MANAGEMENT OF HCC EASL-EORTC Guidelines Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain Levels of Evidence according
More informationThe Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page
The Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page 1674-1679 Radioembolization in Treatment of Hepatocellular Carcinoma with Portal Vein Invasion Elsahhar Ahmed Hetta, Osama Mohamed
More information3/22/2017. I will be discussing off label/investigational use of tivantinib for hepatocellular carcinoma.
Grant/Research Support - AbbVie, Conatus, Hologic, Intercept, Genfit, Gilead, Mallinckrodt, Merck, Salix, Shire, Vital Therapies Consultant AbbVie, Gilead, Merck Member, Scientific Advisory Board Vital
More informationLiver Cancer: Diagnosis and Treatment Options
Liver Cancer: Diagnosis and Treatment Options Fred Poordad, MD Chief, Hepatology University Transplant Center Professor of Medicine UT Health, San Antonio VP, Academic and Clinical Affairs, Texas Liver
More informationHCC RADIOLOGIC DIAGNOSIS
UCSF Transplant 2010 THE BEFORE AND AFTER HEPATOCELLULAR CARCINOMA MANAGEMENT Francis Yao, M.D. Professor of Clinical Medicine and Surgery Medical Director, Liver Transplantation University of California,
More informationInterventional Radiology in Liver Cancer. Nakarin Inmutto MD
Interventional Radiology in Liver Cancer Nakarin Inmutto MD Liver cancer Primary liver cancer Hepatocellular carcinoma Cholangiocarcinoma Metastasis Interventional Radiologist Diagnosis Imaging US / CT
More informationFirst-line therapy for unresectable HCC:
ESMO GI Cancer Preceptorship 15 November 2017 Singapore First-line therapy for unresectable HCC: an oncologist s viewpoint Chiun Hsu, MD, PhD G raduate I n stitute of Oncology, National Taiwan Univers
More informationLiver Directed Therapy for Hepatocellular Carcinoma
Liver Directed Therapy for Hepatocellular Carcinoma Anil K Pillai MD, FRCR, Associate Professor, Department of Radiology UT Houston Health Science Center, Houston, TX, United States. Hepatocellular cancer
More informationRADIATION SEGMENTECTOMY. Robert J Lewandowski, MD
RADIATION SEGMENTECTOMY Robert J Lewandowski, MD Robert Lewandowski, M.D. Consultant/Advisory Board: Cook Medical, LLC, Arsenal, BTG International, Boston Scientific Corp., ABK Reference Unlabeled/Unapproved
More informationUpdate EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma
Update EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma Peter R. Galle PHC 2018 - www.aphc.info Disclosure of Conflict of Interest Peter R. Galle I have the following financial
More informationTreatment of Hepatocellular Carcinoma. Andrew J. Muir, MD MHS Division of Gastroenterology Duke University Medical Center
Treatment of Hepatocellular Carcinoma Andrew J. Muir, MD MHS Division of Gastroenterology Duke University Medical Center Epidemiology of HCC: world The 5 th most common cancer worldwide > 500, 000 new
More informationDisclosure. Speaker name: Prof. Maciej Pech I have the following potential conflicts of interest to report:
Disclosure Speaker name: Prof. Maciej Pech I have the following potential conflicts of interest to report: Consulting Employment in industry Stockholder of a healthcare company Owner of a healthcare company
More informationSelection Criteria and Insertion of SIRT into HCC Treatment Guidelines
Selection Criteria and Insertion of SIRT into HCC Treatment Guidelines 2 nd Asia Pacific Symposium on Liver- Directed Y-90 Microspheres Therapy 1st November 2014, Singapore Pierce Chow FRCSE PhD SIRT in
More informationHepatocellular Carcinoma
Hepatocellular Carcinoma Luis S. Marsano, MD Professor of Medicine Division of Gastroenterology, Hepatology, & Nutrition University of Louisville & Louisville VAMC 2010 Magnitude of the Problem 95% of
More informationSelective Internal Radiation Therapy (SIRT) in the multimodal approach to Hepatocellular Carcinoma
Selective Internal Radiation Therapy (SIRT) in the multimodal approach to Hepatocellular Carcinoma International Course on THERANOSTICS and MOLECULAR RADIOTHERAPY Brussels, 4 october 2017 Vincent Donckier
More informationOptimal management of HCC: in Asia
Optimal management of HCC: in Asia Kwang-Hyub Han, MD Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea Newly diagnosed HCC : > 70% occur
More informationThe Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present:
The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present: Certified by: Provided by: Endorsed by: Hepatocellular Carcinoma HCC: Age
More informationLiver and Biliary Tract Cancers Critical Review
Liver and Biliary Tract Cancers Critical Review Lorenza Rimassa Oncologia Medica e Ematologia Humanitas Cancer Center Humanitas Research Hospital Rozzano (Milano) Critical review Oral presentations Melero
More informationUPDATE TO THE MANAGEMENT OF PATIENTS WITH HCC HCA
UPDATE TO THE MANAGEMENT OF PATIENTS WITH HCC HUSSEIN K. MOHAMED MD, FACS. Transplant and Hepato-biliary Surgery Largo Medical Center HCA DISCLOSURE I have no financial relationship(s) relevant to the
More informationInterventional Radiologic Treatment of Hepatocellular Carcinoma
Interventional Radiologic Treatment of Hepatocellular Carcinoma Fatih Boyvat Abstract The current treatment modalities for patients with hepatocellular carcinoma are discussed in this review. Hepatocellular
More informationLearning Objectives. After attending this presentation, participants will be able to:
Learning Objectives After attending this presentation, participants will be able to: Describe HCV in 2015 Describe how to diagnose advanced liver disease and cirrhosis Identify the clinical presentation
More informationTumor incidence varies significantly, depending on geographical location.
Hepatocellular carcinoma is the 5 th most common malignancy worldwide with male-to-female ratio 5:1 in Asia 2:1 in the United States Tumor incidence varies significantly, depending on geographical location.
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C
More informationLife After SVR for Cirrhotic HCV
Life After SVR for Cirrhotic HCV KIM NEWNHAM MN, NP CIRRHOSIS CARE CLINIC UNIVERSITY OF ALBERTA Objectives To review the benefits of HCV clearance in cirrhotic patients To review some of the emerging data
More informationPamplona, junio de Futuro de la Hepatología: Cáncer Hepático. Bruno Sangro Clínica Universidad de Navarra. IDISNA. CIBERehd.
Pamplona, junio de 2008 Futuro de la Hepatología: Cáncer Hepático Bruno Sangro Clínica Universidad de Navarra. IDISNA. CIBERehd. Pamplona, Spain Etiología del Cáncer Hepático HBV HCV Alcohol NAFLD Iron
More informationRETHINKING OUR APPROACH TO INTERMEDIATE-SIZE HCC
SATELLITE SYMPOSIUM Emerging Horizons in HCC: From Palliation to Cure RETHINKING OUR APPROACH TO INTERMEDIATE-SIZE HCC Professor Riccardo Lencioni, MD, FSIR, EBIR University of Pisa School of Medicine,
More information蕾莎瓦 Nexavar 臨床試驗資料 (HCC 肝細胞癌 )
蕾莎瓦 Nexavar 臨床試驗資料 (HCC 肝細胞癌 ) 1 Sorafenib Improves Survival in Hepatocellular Carcinoma: Results of a Phase III Randomized, -Controlled Trial Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip
More informationSurgical management of HCC. Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London
Surgical management of HCC Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London Global distribution of HCC and staging systems WEST 1. Italy (Milan,
More informationNew Insights: Systemic Therapy for Advanced Hepatocellular Carcinoma (HCC)
New Insights: Systemic Therapy for Advanced Hepatocellular Carcinoma (HCC) Thomas W.T. Leung Associate Director and Honorary Consultant Comprehensive Oncology Centre Hong Kong Sanatorium and Hospital Hong
More informationHepatocellular Carcinoma: Transplantation, Resection or Ablation?
Hepatocellular Carcinoma: Transplantation, Resection or Ablation? Roberto Gedaly MD Chief, Abdominal Transplantation Transplant Service Line University of Kentucky Nothing to disclose Disclosure Objective
More informationA New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Published online: March 9, 2017 Editorial A New Era of Systemic Therapy for Hepatocellular Carcinoma with Prof. M. Kudo Editor Liver Cancer Introduction The SHARP study in 2007 [1] and the Asia Pacific
More informationStaging & Current treatment of HCC
Staging & Current treatment of HCC Dr.: Adel El Badrawy Badrawy; ; M.D. Staging & Current ttt of HCC Early stage HCC is typically silent. HCC is often advanced at first manifestation. The selective ttt
More informationNexavar in advanced HCC: a paradigm shift in clinical practice
Nexavar in advanced HCC: a paradigm shift in clinical practice Tim Greten Hanover Medical School, Germany Histopathological progression and molecular features of HCC Chronic liver disease Liver cirrhosis
More informationTACE: coming of age?
Invasive procedures in the diagnosis and treatment of liver diseases: focal lesions F.Farinati Gastroenterologia, Padova TACE: coming of age? AISF 2005 TACE: LEVELS OF EVIDENCE Degree of certainty Methodology
More informationRADIOEMBOLIZZAZIONE NEI TUMORI EPATICI: STATO DELL ARTE. clic per modificare lo stile del sottotitolo dello schem
XII Congresso Nazionale AIMN 2015 16-19 Aprile 2015 Rimini RADIOEMBOLIZZAZIONE NEI TUMORI EPATICI: STATO DELL ARTE clic per modificare lo stile del sottotitolo dello schem Marco Maccauro Nuclear Medicine
More informationLiver Transplantation Evaluation: Objectives
Liver Transplantation Evaluation: Essential Work-Up Curtis K. Argo, MD, MS VGS/ACG Regional Postgraduate Course Williamsburg, VA September 13, 2015 Objectives Discuss determining readiness for transplantation
More informationClinical Staging for Hepatocellular Carcinoma: Eastern Perspectives. Osamu Yokosuka, M.D. Graduate School of Medicine, Chiba University, Chiba, Japan
Clinical Staging for Hepatocellular Carcinoma: Eastern Perspectives Osamu Yokosuka, M.D. Graduate School of Medicine, Chiba University, Chiba, Japan Why is staging system important? Cancer stage can be
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis
More informationTherapeutic Response Assessment and Endpoints in HCC
APASL HCC Conference, 2013 Cebu Therapeutic Response Assessment and Endpoints in HCC Ronnie T.P. Poon, MBBS, MS, PhD Chair Professor of Surgery Chief of Hepatobiliary and Pancreatic Surgery The University
More informationMultidisciplinary Treatment Strategies for Primary and Metastatic Liver Cancers
Multidisciplinary Treatment Strategies for Primary and Metastatic Liver Cancers Ching-Wei D. Tzeng, M.D. Assistant Professor Surgical Oncology University of Kentucky Markey Cancer Center Affiliate Network
More informationAdvances in percutaneous ablation for hepatocellular carcinoma
Advances in percutaneous ablation for hepatocellular carcinoma P. Nahon1,2,3 1 Hepatology, Jean Verdier Hospital, APHP, Bondy, France 2 Paris 13 university, Sorbonne Paris Cité, UFRSMBH, Bobigny, France
More informationTrans-arterial radioembolisation (TARE) of unresectable HCC using Y-90 microspheres: is it dangerous in case of portal vein thrombosis?
Trans-arterial radioembolisation (TARE) of unresectable HCC using Y-90 microspheres: is it dangerous in case of portal vein thrombosis? Poster No.: C-1634 Congress: ECR 2014 Type: Authors: Keywords: DOI:
More informationHepatocellular carcinoma: from guidelines to individualized treatment
AISF 2012 Rome, 22-24 February 2012 Hepatocellular carcinoma: from guidelines to individualized treatment A.D. 1088 Luigi Bolondi Professor of Medicine, Chairman Department of Digestive Diseases and Internal
More informationHepatocellular Carcinoma in Qatar
Hepatocellular Carcinoma in Qatar K. I. Rasul 1, S. H. Al-Azawi 1, P. Chandra 2 1 NCCCR, 2 Medical Research Centre, Hamad Medical Corporation, Doha, Qatar Abstract Objective The main aim of this study
More informationRadiation Therapy for Liver Malignancies
Outline Radiation Therapy for Liver Malignancies Albert J. Chang, M.D., Ph.D. Department of Radiation Oncology, UCSF March 23, 2014 Rationale for developing liver directed therapies Liver directed therapies
More informationTreatment of HCC in real life-chinese perspective
Treatment of HCC in real life-chinese perspective George Lau MBBS (HK), MRCP(UK), FHKCP, FHKAM (GI), MD(HK), FRCP (Edin, Lond), FAASLD (US) Chairman Humanity and Health Medical Group, Hong Kong SAR, CHINA
More informationINTERMEDIATE HEPATOCELLULAR CARCINOMA MANAGEMENT
INTERMEDIATE HEPATOCELLULAR CARCINOMA MANAGEMENT GI Preceptorship Nov 2018 Dr Choo Su Pin Senior Consultant and Deputy Head, Medical Oncology Co-Chair, Comprehensive Liver Cancer Centre National Cancer
More informationHow to evaluate tumor response? Yonsei University College of Medicine Kim, Beom Kyung
How to evaluate tumor response? Yonsei University College of Medicine Kim, Beom Kyung End points in research for solid cancers Overall survival (OS) The most ideal one, but requires long follow-up duration
More informationScreening for HCCwho,
Screening for HCCwho, how and how often? Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital HCC Global Epidemiology
More informationFor personal use only
Sirtex Medical Limited SARAH Clinical Study Results Investor Presentation Nigel Lange, Interim CEO Dr David N. Cade, CMO 24 April 2017 SIR-Spheres is a registered trademark of Sirtex SIR-Spheres Pty Ltd
More informationAssessment of Liver Function: Implications for HCC Treatment
Assessment of Liver Function: Implications for HCC Treatment A/P Dan Yock Young MBBS, PhD, MRCP, MMed. FAMS Chair, University Medicine Cluster. NUHS Head, Department of Medicine, National University of
More informationPercutaneous ablation: indications, techniques and results
Percutaneous ablation: indications, techniques and results Giovan Giuseppe Di Costanzo Dipartimento dei Trapianti UOSC Epatologia AORN A Cardarelli - Napoli Treatment algorithm EASL, EORTC guidelines HCC
More information